Inferra AI / Company / AMLX
Amylyx Pharmaceuticals, Inc.
AMLX · Health Care
Last earnings Aug 6, 2026
AI analysis
Q2 2025 · reported Aug 7, 2025
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
The event-summary record for this company carries no extracted figures, so the brief and charts cannot be drawn yet. The summary below and the held documents are the record for this event.
Guidance · company-stated
No guidance located in the held release
Capital allocation
The Company expects that its cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12 months from the issuance of these consolidated financial statements.
To continue its development efforts, the Company may need to obtain substantial additional funding through public or private equity offerings, debt financings, collaborations, strategic alliances and/or licensing arrangements in order to fund its research and development and ongoing operating expenses.
Event summary
Amylyx Pharmaceuticals, Inc. Q2 2025 results
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
No guidance located in the held release
Capital allocation
The Company expects that its cash, cash equivalents and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12 months from the issuance of these consolidated financial statements.
SEC original ↗Amylyx Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 6, 2026
To continue its development efforts, the Company may need to obtain substantial additional funding through public or private equity offerings, debt financings, collaborations, strategic alliances and/or licensing arrangements in order to fund its research and development and ongoing operating expenses.
SEC original ↗Amylyx Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 6, 2026
The Company adjusts the cost of available-for-sale debt securities for amortization of premiums and accretion of discounts to maturity.
SEC original ↗Amylyx Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 6, 2026
The Company includes interest and dividends on securities classified as available-for-sale in interest income.
SEC original ↗Amylyx Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 6, 2026
Holders of common stock are entitled to receive dividends, as may be declared by the Company s Board of Directors, if any, subject to the preferential dividend rights of the preferred stock.
SEC original ↗Amylyx Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 6, 2026
No dividends were declared or paid during the six months ended June 30, 2026 and 2025 .
SEC original ↗Amylyx Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 6, 2026
Strategy & priorities
We remain focused on disciplined execution across our programs.
SEC original ↗Amylyx Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Under the FDA’s Fast Track Designation, AMX0114 is eligible for more frequent meetings and communications with the FDA, as well as Priority Review if relevant criteria continue to be met.
SEC original ↗Amylyx Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
We are currently focused on three investigational therapies across several neurodegenerative and endocrine diseases in which we believe they can make the greatest impact.
SEC original ↗Amylyx Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
To continue its development efforts, the Company may need to obtain substantial additional funding through public or private equity offerings, debt financings, collaborations, strategic alliances and/or licensing arrangements in order to fund its research and development and ongoing operating expenses.
SEC original ↗Amylyx Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 6, 2026
The Company may not be able to obtain financing on acceptable terms, when needed or at all, and the Company may not be able to enter into collaborations, strategic alliances or licensing arrangements.
SEC original ↗Amylyx Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 6, 2026
Risks & headwinds
Where others see challenges, we see opportunities that we pursue with urgency, rigorous science, and unwavering commitment to the communities we serve.
SEC original ↗Amylyx Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.
SEC original ↗Amylyx Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Any forward-looking statements in this press release and related comments in the Company's earnings conference call are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements.
SEC original ↗Amylyx Pharmaceuticals, Inc. — Earnings release (8-K exhibit)EX-99Aug 7, 2025
Legal Proceedings 27 Item 1A.
SEC original ↗Amylyx Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 6, 2026
These statements are not guarantees of future results or performance and involve substantial risks and uncertainties.
SEC original ↗Amylyx Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 6, 2026
Any forward-looking statements in this Quarterly Report reflect our current views with respect to future events and with respect to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements.
SEC original ↗Amylyx Pharmaceuticals, Inc. — 10-Q Quarterly report10-QAug 6, 2026
Earnings deck slides
0 decks with slide viewAmylyx Pharmaceuticals, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Amylyx Pharmaceuticals, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
33 documents- Q2 2026
- 8-KAMLX
- 8-KAMLX
- 8-KAMLX
- EX-99AMLX
- 8-KAMLX
- EX-99AMLX
- 8-KAMLX
- EX-99AMLX
- 10-QAMLX
- Q1 2026
- 8-KAMLX
- 8-KAMLX
- 10-QAMLX
- Q4 2025
- 8-KAMLX
- 8-KAMLX
- 10-KAMLX
- 8-KAMLX
- Q3 2025
- 8-KAMLX
- 10-QAMLX
- Q2 2025
- 8-KAMLX
- 8-KAMLX
- 8-KAMLX
- 10-QAMLX
- Q1 2025
- 8-KAMLX
- 8-KAMLX
- 10-QAMLX
- Q4 2024
- 8-KAMLX
- 10-KAMLX
- 8-KAMLX
- Q3 2024
- 8-KAMLX
- 8-KAMLX
- 10-QAMLX
- 8-KAMLX
- Q2 2024
- 10-QAMLX
Earnings releases
7 documentsPresentations
2 documents
Transcripts
0 documentsNo transcripts for Amylyx Pharmaceuticals, Inc. are held in this edition of the library.
See also the earnings calendar for every tracked company’s next earnings date.